Subscribe to RSS
DOI: 10.1055/a-1519-3587
In vitro evaluation of potential interference of lokivetmab with protein electrophoresis and immunofixation
In-vitro-Evaluierung einer möglichen Interferenz zwischen Lokivetmab und Proteinelektrophorese oder ImmunfixationAbstract
Objective In humans, misdiagnoses of monoclonal gammopathy after use of therapeutic monoclonal antibodies has been documented. This triggers concerns for similar misdiagnoses in animals treated with monoclonal antibodies. The aim of this study was to evaluate if lokivetmab interferes with serum protein electrophoresis and immunofixation electrophoresis in dogs.
Material and methods Residual sera from 25 client-owned, healthy blood donor dogs from 2 veterinary hospitals in Germany were used. The residual sera were analysed with serum protein electrophoresis and immunofixation electrophoresis before and after being spiked with lokivetmab at a concentration of 10 µg/ml (corresponding to the mean peak serum concentration after a subcutaneous injection of 2 mg/kg lokivetmab).
Results No monoclonal gammopathy was observed on serum protein electrophoresis and all proteins had a normal distribution pattern without any pathologic bands on immunofixation electrophoresis. The absolute γ-globulin values of spiked samples, however, were significantly higher than in the native sera although they remained within the reference interval. No other globulin fractions were significantly different.
Conclusion and clinical relevance This study suggests that lokivetmab at a dose of 2 mg/kg is not detected as a monoclonal peak on serum protein electrophoresis or immunofixation electrophoresis, and thus is unlikely to lead to a misdiagnosis of other diseases that are characterised by monoclonal gammopathies.
Zusammenfassung
Ziel Beim Menschen wurden Fehldiagnosen einer monoklonalen Gammopathie nach Verwendung therapeutischer monoklonaler Antikörper dokumentiert. Dies löst Bedenken hinsichtlich ähnlicher Fehldiagnosen bei Tieren aus, die mit monoklonalen Antikörpern behandelt wurden. Ziel dieser Studie war zu evaluieren, ob Lokivetmab mit der Serumproteinelektrophorese und der Immunfixationselektrophorese bei Hunden interferiert.
Material und Methoden Zur Untersuchung gelangten übrig gebliebene Serumproben von 25 privat gehaltenen, gesunden Blutspenderhunden aus 2 Tierkliniken in Deutschland. Die Serumproben wurden vor und nach der Mischung mit Lokivetmab in einer Konzentration von 10 µg/ml mittels Serumproteinelektrophorese und Immunfixationselektrophorese analysiert. Die gewählte Konzentration entspricht der mittleren maximalen Serumkonzentration nach einer subkutanen Injektion von 2 mg/kg Lokivetmab.
Ergebnisse Bei der Serumproteinelektrophorese zeigte sich keine monoklonale Gammopathie und bei der Immunfixationselektrophorese wiesen alle Proteine ein normales Verteilungsmuster ohne pathologische Banden auf. Die absoluten γ-Gammaglobulin-Werte der aufgestockten Proben waren jedoch signifikant höher als die der nativen Seren, blieben jedoch im Referenzintervall. Die anderen Globulinfraktionen differierten nicht signifikant.
Schlussfolgerung und klinische Relevanz Die Ergebnisse legen nahe, dass Lokivetmab in einer Dosis von 2 mg/kg nicht als monoklonaler Peak bei der Serumprotein- oder Immunfixationselektrophorese erkannt wird und daher wahrscheinlich nicht zu einem fälschlichen Verdacht einer mit einer monoklonalen Gammopathie einhergehenden Erkrankung führt.
*Neoklis Apostolopoulos and Athanasia Mitropoulou are joint first author.
ID https://orcid.org/0000-0001-9749-0795
Zusatzmaterial
- Zusätzliches Material finden Sie unter https://doi.org/10.1055/a-1519-3587
- Supplementary material
Publication History
Received: 10 November 2020
Accepted: 22 December 2020
Article published online:
23 August 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Bustamante-Córdova L, Melgoza-González EA, Hernández J. Recombinant Antibodies in Veterinary Medicine: An Update. Front Vet Sci 2018; 5: 175 DOI: 10.3389/fvets.2018.00175.
- 2 Michels GM, Ramsey DS, Walsh KF. et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016; 27 (06) 478-e129 DOI: 10.1111/vde.12376.
- 3 Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol 2011; 155 (01) 123-125 DOI: 10.1111/j.1365-2141.2011.08644.x.
- 4 McCudden CR, Voorhees PM, Hainsworth SA. et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010; 56 (12) 1897-1899 DOI: 10.1373/clinchem.2010.152116.
- 5 Willrich MAV, Ladwig PM, Andreguetto BD. et al. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin Chem Lab Med 2016; 54 (06) 1085-1093 DOI: 10.1515/cclm-2015-1023.
- 6 Liu L, Shurin MR, Wheeler SE. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis. Clin Biochem 2020; 75: 40-47 DOI: 10.1016/j.clinbiochem.2019.10.011.
- 7 Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol 2017; 6 (09) 576-588 DOI: 10.1002/psp4.12224.
- 8 Committee for Medicinal Products for Veterinary Use. CVMP assessment report for CYTOPOINT (EMEA/V/C/003939/0000). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/003939/WC500226926.pdf accessed: 31.03.2020
- 9 Stockham SL, Scott MA. Fundamentals of Veterinary Clinical Pathology. 2nd ed.. Ames, Iowa: Wiley-Blackwell; 2008
- 10 Leontides LS, Saridomichelakis MN, Billinis C. et al. A cross-sectional study of Leishmania spp. infection in clinically healthy dogs with polymerase chain reaction and serology in Greece. Vet Parasitol 2002; 109 (01/02) 19-27 DOI: 10.1016/S0304-4017(02)00201-7.
- 11 Saridomichelakis M, Koutinas A, Gioulekas D. et al. Canine atopic dermatitis in Greece. Clinical observations and the prevalence of positive intradermal test reactions in 91 spontaneous cases. Vet Immunol Immunopathol 1999; 69 (01) 61-73 DOI: 10.1016/S0165-2427(99)00040-9.
- 12 Tater KC, Jackson HA, Paps J. et al. Effects of routine prophylactic vaccination or administration of aluminum adjuvant alone on allergen-specific serum IgE and IgG responses in allergic dogs. Am J Vet Res 2005; 66 (09) 1572-1577
- 13 Wardrop KJ, Birkenheuer A, Blais MC. et al. Update on Canine and Feline Blood Donor Screening for Blood-Borne Pathogens. J Vet Intern Med 2016; 30 (01) 15-35 DOI: 10.1111/jvim.13823.
- 14 Nahm FS. Nonparametric statistical tests for the continuous data: the basic concept and the practical use. Korean J Anesthesiol 2016; 69 (01) 8-14 DOI: 10.4097/kjae.2016.69.1.8.
- 15 Mathiesen R, Chriél M, Struve T. et al. Quantitative immunoassay for mink immunoglobulin in serum and milk. Acta Vet Scand 2018; 60 (01) 36 DOI: 10.1186/s13028-018-0391-7.
- 16 Wang W-H, Cheung-Lau J, Chen Y. et al. Specific and high-resolution identification of monoclonal antibody fragments detected by capillary electrophoresis-sodium dodecyl sulfate using reversed-phase HPLC with top-down mass spectrometry analysis. MAbs 2019; 11 (07) 1233-1244 DOI: 10.1080/19420862.2019.1646554.